Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent
dc.contributor.author | Nguyen, Ashley | |
dc.contributor.author | Chow, Diana S-L | |
dc.contributor.author | Wu, Lei | |
dc.contributor.author | Teng, Yang Angela | |
dc.contributor.author | Sarkar, Mahua | |
dc.contributor.author | Toups, Elizabeth G | |
dc.contributor.author | Harrop, James S | |
dc.contributor.author | Schmitt, Karl M | |
dc.contributor.author | Johnson, Michele M | |
dc.contributor.author | Guest, James D | |
dc.contributor.author | Aarabi, Bizhan | |
dc.contributor.author | Shaffrey, Christopher I | |
dc.contributor.author | Boakye, Maxwell | |
dc.contributor.author | Frankowski, Ralph F | |
dc.contributor.author | Fehlings, Michael G | |
dc.contributor.author | Grossman, Robert G | |
dc.date.accessioned | 2021-07-26T19:21:45Z | |
dc.date.available | 2021-07-26T19:21:45Z | |
dc.date.issued | 2021-04-28 | |
dc.identifier.uri | http://hdl.handle.net/10713/16231 | |
dc.description.abstract | Riluzole, a benzothiazole sodium channel blocker that received US Food and Drug Administration approval to attenuate neurodegeneration in amyotrophic lateral sclerosis in 1995, was found to be safe and potentially efficacious in a spinal cord injury (SCI) population, as evident in a phase I clinical trial. The acute and progressive nature of traumatic SCI and the complexity of secondary injury processes can alter the pharmacokinetics of therapeutics. A 1-compartment with first-order elimination population pharmacokinetic model for riluzole incorporating time-dependent clearance and volume of distribution was developed from combined data of the phase 1 and the ongoing phase 2/3 trials. This change in therapeutic exposure may lead to a biased estimate of the exposure-response relationship when evaluating therapeutic effects. With the developed model, a rational, optimal dosing scheme can be designed with time-dependent modification that preserves the required therapeutic exposure of riluzole. © 2021 The Authors.. | en_US |
dc.description.uri | https://doi.org/10.1002/jcph.1876 | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley-Blackwell | en_US |
dc.relation.ispartof | Journal of Clinical Pharmacology | en_US |
dc.rights | © 2021 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology. | en_US |
dc.subject | pharmacokinetics | en_US |
dc.subject | population modeling | en_US |
dc.subject | riluzole | en_US |
dc.subject | spinal cord injury | en_US |
dc.title | Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1002/jcph.1876 | |
dc.identifier.pmid | 33908635 | |
dc.source.country | England |